Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a Real-World Database

Expert Review of Endocrinology & Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 6

Published: Feb. 3, 2025

Interest has grown in glucagon-like peptide-1 receptor-agonist (GLP-1 RA) semaglutide long-term outcomes. This retrospective cohort study compared effectiveness of oral and subcutaneous for weight loss outcomes adults with type 2 diabetes (T2D) over a 2-year treatment period. Weight was evaluated through mean percentage change from baseline, proportion achieving at least 5% 10% comparing (n = 310) versus users 57) by age group. Subcutaneous experienced 7.5% (16.7 pounds) 58.7% 32.9% ≥5% ≥10% loss, respectively. Oral lost 4.4% (8.7 50.9% 17.5% Significant differences existed between formulations (p-value <0.01) 0.03), but not 0.34). Outcomes differed within 0.02). Regression analyses adjusted confounders yielded similar findings. achieved superior to users. Older better younger However, no were observed

Language: Английский

---

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation

Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 156057 - 156057

Published: Oct. 1, 2024

Language: Английский

---

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP‐1RA‐based weight‐loss therapies

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as key agents for weight management, based on their marked efficacy observed in randomized controlled trials. While still limited, real‐world studies GLP‐1RA use populations with obesity are increasingly available. This narrative review discusses contemporary evidence demonstrating the utilization, clinical and comparative effectiveness, adverse effects of currently approved GLP‐1RA‐based weight‐loss therapies, that is, liraglutide, semaglutide tirzepatide. The reduction practice overall tends to be lower than trials; however, outcomes approach those seen trials when focusing highly adherent patients. Real‐world demonstrate high discontinuation rates GLP‐1RAs (20%–50%) within first year, much doses evaluated Evidence from observational type 2 diabetes or suggests frequent gastrointestinal disturbances users, also trials, but no clear increase risks severe events like pancreatitis pancreatic cancer, thyroid disorders, depression self‐harm. Further is needed understand possible associations eye disease other rare outcomes. We provide 10 areas particular importance further research space, including improved understanding exact drivers early suboptimal dosing, stopping treatment, investigations cost‐effectiveness hard settings, not only cardio‐reno‐metabolic obesity‐induced diseases neuropsychiatric disease, musculoskeletal infections. Plain Language Summary Recent advancements medications sparked a lot interest. so‐called GLP‐1 agonist gained attention, because they shown very effective, leading significant loss patients participating GLP‐1RAs, semaglutide, tirzepatide, help manage by mimicking hormones control blood sugar appetite. However, how these perform real life can different settings which carefully selected treatment plans closely followed. literature looks at used effectiveness safety settings. In real‐life practice, often less effective trial conditions. usually don't follow medication strictly data shows many do stick participants might, loss. who achieve results similar A major issue stop using them year due side costs medications, especially if covered insurance. Common include nausea digestive problems, main reasons taking treatments. These manageable decrease over time, this reviews found strong cause users. Despite challenges, effectively consistently, show substantial benefits loss, most so newest likely prevent weight‐related health conditions cardiovascular beneficial scarce emphasizes need more why improve dosing. It calls long‐term therapies various outcomes, mental health, cardiometabolic diseases. Overall, while valuable tool requires careful consideration individual patient factors, such ability plans, effects, afford medications. will make treatments wider range people them.

Language: Английский

---

The Perceptions of and Attitudes Toward Obesity in Bulgarian Adults with a BMI ≥ 25.0 kg/m2—An Exploratory Study

Nutrients, Journal Year: 2025, Volume and Issue: 17(3), P. 373 - 373

Published: Jan. 21, 2025

Background: Obesity affects 33.2% of the adult population in Bulgaria, and there is a scarcity information about affected individuals’ attitudes toward their weight situation. The aim this study was to explore perceptions obesity adults. Methods: present involved questionnaire-based survey that utilized home-based tablet-assisted face-to-face interviews. Interviewees comprised individuals aged 25–64 y/o with BMI > 25.0 kg/m2. Results: Overall, 704 respondents participated (344 overweight; 360 obese). Over 50% participants reported attempts reduce weight, only 6% overweight group 16% obese perceiving condition as worrisome. One-third considered state temporary. main cause for alarm overweight/obese worsening overall physical males an increase clothes size females. need urgent reduction body noted by 12% 40% respondents. reasons being were collated lack activity (noted 52% participants), sedentary lifestyle (51%), stress/depression (41%), excessive consumption carbohydrates (34%), general overconsumption food (33%), poor quality products (28%). Of note, 56% had first consulted medical professional overweight. Most selected dieting without reduction, 48% stating they would try drugs approved reduction. Conclusions: Many have unrealistic self-perception very low motivation take active measures. These discrepancies offer great opportunities better public education structured, strategies.

Language: Английский

---

Genetically determined physical activity levels, sedentary behaviours, and their association with the risk of age-related macular degeneration

Journal of International Medical Research, Journal Year: 2025, Volume and Issue: 53(2)

Published: Feb. 1, 2025

Objective To investigate the causal effects of physical activity and sedentary traits on risk Age-related macular degeneration (AMD). Methods A two-sample Mendelian randomization (MR) analysis was used to relationship between AMD. We genome-wide association studies (GWAS) summary statistics from two publicly available biobank-scale cohorts: UK Biobank FinnGen. Physical data were self-reported by 703,901 participants behaviour gathered 159,606 FinnGen participants. Our primarily inverse variance weighted (IVW) method. Result Engaging in moderate-to-vigorous significantly reduced AMD with an odds ratio 0.77 (95% CI: 0.66–0.89). However, leisure screen time showed a slight but non-statistically significant upward trend. Sedentary at work, commuting no risk. Conclusions This study MR examine activity, behaviour, It offers genetic evidence suggesting that may protect against AMD, emphasizing significance lifestyle factors maintaining ocular health.

Language: Английский

---

Exploring the perceptions of obesity, health habits, stigma, and eating behaviors in Brazil

Diabetology & Metabolic Syndrome, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 7, 2025

Obesity is a chronic and complex disease influenced by various factors that hinder weight loss maintenance. However, perceptions of obesity are often marked stigma. This study assessed obesity, stigma, health habits, emotional eating in representative sample the Brazilian population. cross-sectional included 2560 participants. Data were collected from structured online questionnaires covering demographic aspects, behaviors related to eating. The prevalence was 26%. 61% these individuals did not receive formal diagnosis. Although 76% participants considered disease, 65% believed diet exercise sufficient treatments. Only 5% with 10% beneficial for associated comorbidities. It widely normalizing body mass index (BMI) necessary positive outcomes. Emotional slightly more prevalent among (25%) but present across all BMI ranges. findings this investigation underscore necessity comprehensive education regarding as multifactorial condition. They emphasize importance promoting awareness benefits modest reduction, improving diagnosis documentation clinical settings, implementing targeted interventions address misconceptions concerning treatment modalities impact behaviors.

Language: Английский

---

The Use of an Artificial Intelligence Platform OpenEvidence to Augment Clinical Decision-Making for Primary Care Physicians

Journal of Primary Care & Community Health, Journal Year: 2025, Volume and Issue: 16

Published: April 1, 2025

Background: Artificial intelligence (AI) platforms can potentially enhance clinical decision-making (CDM) in primary care settings. OpenEvidence (OE), an AI tool, draws from trusted sources to generate evidence-based medicine (EBM) recommendations address questions. However, its effectiveness real-world cases remains unknown. Objective: To evaluate the performance of OE providing EBM for five common chronic conditions care: hypertension, hyperlipidemia, diabetes mellitus type 2, depression, and obesity. Methods: Five patient were retrospectively analyzed. Physicians posed specific questions, responses evaluated on clarity, relevance, evidence support, impact CDM, overall satisfaction. Four independent physicians provided ratings using a 0 4 scale. Results: accurate, all cases, aligning with physician plans. was scored scale zero four, where very unclear, four clear. Mean scores across clarity (3.55 ± 0.60), relevance (3.75 0.44), support (3.35 0.49), satisfaction (3.60 0.60). CDM limited (1.95 1.05), as primarily reinforced rather than modified Conclusion: rated high reinforcing decisions conditions. While minimal due study’s retrospective nature, shows promise augmenting physician. Prospective trials are needed utility complex multidisciplinary

Language: Английский

---

Heightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists

JAMA Internal Medicine, Journal Year: 2024, Volume and Issue: 184(10), P. 1158 - 1158

Published: Aug. 5, 2024

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Dermatology Health Forum Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

---

Demystifying Obesity: Understanding, Prevention, Treatment, and Stigmas

Nutrition Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 17, 2024

Obesity is a complex chronic disease that affects millions of people worldwide. There still significant stigma associated with it, which can lead to discrimination and create additional barriers for who are already in treatment. On the other hand, it noted have serious implications health predisposition noncommunicable diseases. In this sense, objective study was carry out narrative review involving all current elements understanding, prevention, treatment, debate stigmas related obesity. A search conducted 2024 original articles, randomized or nonrandomized clinical trials, systematic reviews, meta-analyses, guidelines following databases: Pubmed, Scielo, Web Science, CrossRef, Google Scholar. The publication period from 2014 2024. influenced by combination genetic, environmental, psychological factors. It encouraging see various emerging points been identified across different fields such as histology, physiology, genetics, weight loss, public policy. These obesity areas certainly warrant attention future studies. Researchers delve into these topics deepen their understanding potentially uncover novel insights. management should be multifactorial individualized each patient. Public policies also play crucial role combating obesity, including promotion, prevention excessive gain, early diagnosis, proper care patients. society begins an extremely element not moral failure lack willpower. This requires change way talk about well practices support instead stigmatizing them. does specific address, color, race. belongs everyone regarded global problem.

Language: Английский

---

How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Annals of Internal Medicine, Journal Year: 2024, Volume and Issue: 177(10), P. 1415 - 1424

Published: Oct. 1, 2024

In 2022, 1 in 8 people the world were living with obesity, and lifestyle interventions that include diet, exercise, behavioral modification have been foundation for management of obesity. Recently, pharmacologic therapies developed newest these being glucagon-like peptide receptor agonists. With development new options, American Gastroenterological Association a guideline 2022 to provide evidence-based recommendations obesity adults recommended, or overweight weight-related complications who had an inadequate response interventions, adding agents over continuing alone. this article, 2 experts review available evidence answer following questions: How effective are treatment obesity? Given how do you engage shared decision-making discussion develop mutually agreed-on plan?

Language: Английский

---